InvestorsHub Logo
Followers 62
Posts 2098
Boards Moderated 0
Alias Born 05/09/2020

Re: None

Friday, 08/07/2020 10:42:24 AM

Friday, August 07, 2020 10:42:24 AM

Post# of 67
This board looks a little stale.

Has anyone been paying attention to the potential of the royalties coming in from CytoDyn under their Leronlimab/PRO 140 purchase agreement from Progenics? ...for 10 years ?

Depending on how "net sales" are measured, this could potentially have a 2020 revenue of $60M-$125M and possibly 2021 $200M-$450M income from Leronlimab/PRO 140 royalties. And beyond that would potentially be greater each year.

Anyone know if any of this is cooked into the stock price yet? Doesn't look like it to me.

Of course all this hinges on CytoDyn's success at getting the product approved and to market.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LNTH News